<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37672915</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>452</Volume><PubDate><Year>2023</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Graph network measures reveal distinct white matter abnormalities in motor and extra-motor brain regions of two UMN-predominant ALS subtypes.</ArticleTitle><Pagination><StartPage>120765</StartPage><MedlinePgn>120765</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2023.120765</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(23)00226-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Routine clinical magnetic resonance imaging (MRI) shows bilateral corticospinal tract (CST) hyperintensity in some patients with upper motor neuron (UMN)-predominant ALS (ALS-CST+) but not in others (ALS-CST-). Although, similar in their UMN features, the ALS-CST+ patient group is significantly younger in age, has faster disease progression and shorter survival than the ALS-CST- patient group. Reasons for the differences are unclear.</AbstractText><AbstractText Label="METHOD">In order to evaluate more objective MRI measures of these ALS subgroups, we used diffusion tensor images (DTI) obtained using single shot echo planar imaging sequence from 1.5&#x202f;T Siemens MRI Scanner. We performed an exploratory whole brain white matter (WM) network analysis using graph theory approach on 45 ALS patients (ALS-CST+) (n&#x202f;=&#x202f;21), and (ALS-CST-) (n&#x202f;=&#x202f;24) and neurological controls (n&#x202f;=&#x202f;14).</AbstractText><AbstractText Label="RESULTS">Significant (p&#x202f;&lt;&#x202f;0.05) differences in nodal degree measure between ALS patients and controls were observed in motor and extra motor regions, supplementary motor area, subcortical WM regions, cerebellum and vermis. Importantly, WM network abnormalities were significantly (p&#x202f;&lt;&#x202f;0.05) different between ALS-CST+ and ALS-CST- subgroups. Compared to neurologic controls, both ALS subgroups showed hubs in the right superior occipital gyrus and cuneus as well as significantly (p&#x202f;&lt;&#x202f;0.05) reduced small worldness supportive of WM network damage.</AbstractText><AbstractText Label="CONCLUSIONS">Significant differences between ALS-CST+ and ALS-CST- subgroups of WM network abnormalities, age of onset, symptom duration prior to MRI, and progression rate suggest these patients represent distinct clinical phenotypes and possibly pathophysiologic mechanisms of ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Venkateswaran</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Electrical and Electronics Engineering, Birla Institute of Technology and Science Pilani, Hyderabad Campus, Hyderabad 500078, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Neuromuscular Center, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: epjpioro@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="Y">White Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017352" MajorTopicYN="N">Echo-Planar Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049292" MajorTopicYN="Y">Leukoaraiosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Diffusion tensor imaging</Keyword><Keyword MajorTopicYN="N">Graph measures</Keyword><Keyword MajorTopicYN="N">White matter</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors do not report any conflict of interest relevant to the present study. EPP has received clinical trial and/or research funding from the ALS Association, Biogen, Inc., Biohaven Pharmaceuticals, NIH/CDC, and the Samuel J. and Connie M. Frankino Charitable Foundation. He has received consulting fees from Argenx, Amylyx, Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Cytokinetics, Inc., ITF Pharma, Inc., MT Pharma America, Inc., Neurotherapia, Inc., and Otsuka America, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>18</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37672915</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2023.120765</ArticleId><ArticleId IdType="pii">S0022-510X(23)00226-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>